The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six months, compared to one month, will improve patency rates of target vessels following peripheral vascular intervention (PVI) without significantly increasing complications, particularly bleeding events.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The proportion of patients eligible who are offered study enrollment
Timeframe: 1 year
The proportion of eligible patients who consent to enrollment and randomization
Timeframe: 1 year
The proportion of enrolled patients who have the primary (composite) event of interest defined at 6 months
Timeframe: 6-months
The proportion of enrolled patients who have the primary (composite) event of interest defined at 12 months
Timeframe: 1 year
The numbers and proportions of patients who have each type of major event
Timeframe: 1 year
The proportions of patients who have major event status recorded at each observation time
Timeframe: 1 year